Soft tissue sarcomas are a rare group of cancers arising in muscles, fat, blood vessels, and connective tissues throughout the body. With over 50 subtypes, treatment depends heavily on the specific type, location, and stage. Surgery and radiation remain central, while chemotherapy and newer targeted drugs are used for advanced disease.
What's actually going on in research
Trials are testing checkpoint inhibitors that help the immune system attack sarcoma, CAR-T cell therapy for synovial sarcoma, drugs targeting specific mutations like NTRK fusions, and combinations of radiation with immune drugs. For rare subtypes like alveolar soft part sarcoma, trials are exploring drugs that cut off blood supply to tumors.
Immune checkpoint inhibitors
Drugs like pembrolizumab and nivolumab show activity in certain sarcoma subtypes, especially when combined with radiation or other immune drugs. Trials are identifying which subtypes respond best.
Targeted fusion therapies
Larotrectinib and entrectinib target NTRK gene fusions found in some sarcomas, with high response rates. Trials are testing similar approaches for other fusion-driven sarcomas.
CAR-T cell therapy
Engineered immune cells targeting the NY-ESO-1 protein are being tested for synovial sarcoma and myxoid liposarcoma. Early trials show responses in people whose disease progressed on standard treatment.
What to know before you search
Eligibility typically depends on sarcoma subtype, whether the cancer is localized or metastatic, prior treatments, and sometimes specific genetic mutations.
What types of trials are currently open
- Targeted therapy trials — Testing drugs that block specific mutations or fusions found in your sarcoma subtype, often pills taken daily.
- Immunotherapy trials — Testing checkpoint inhibitors, CAR-T cells, or combinations of immune drugs, sometimes with radiation.
- Combination trials — Testing chemotherapy combined with targeted drugs or immune drugs to see if the combination works better than either alone.
- Radiation trials — Testing new radiation techniques or timing, often combined with surgery or systemic therapy.
- Observational studies — Collecting tissue samples and tracking outcomes to better understand rare sarcoma subtypes and what predicts treatment response.
Recently added Soft Tissue Sarcoma trials
A Multicenter Phase II Clinical Trial Evaluating 68Ga-HX01 Injection for PET/CT Imaging
soft tissue sarcoma
Zemetostat With Anlotinib in Patients With Recurrent/Metastatic Head and Neck Soft Tissue Sarcoma
This is a single-center, single-arm, prospective, Phase II clinical study designed to evaluate the efficacy and safety of zemetostat combined with anlotinib in patients with head-and-neck soft-tissue sarcoma featuring SWI/SNF complex deficiency whose disease has progressed following standard-of-care therapy. Enrolled patients receive zemetostat plus anlotinib until discontinuation criteria are met. The specific dosing regimen is as follows: zemetostat 350 mg orally twice daily (bid po). The recommended dose of anlotinib is 12 mg once daily for 14 consecutive days, followed by a 7-day drug-free interval (2/1 schedule), constituting a 21-day treatment cycle. Doses should be taken at approximately the same time each day. If a patient vomits or misses a dose, no supplemental dose should be administered on that day; the subsequent scheduled dose should be taken as usual.
Find Soft Tissue Sarcoma trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.